Publications

5808 Results

A phase III randomized intergroup trial (S0016) comparing CHOP + rituximab vs. CHOP + iodine-131-tositumomab for front-line treatment of follicular lymphoma: subset analyses and comparison of prognostic models

Authors
OW Press;J Unger;M Leblanc;L Rimsza;J Friedberg;M Czuczman;M Kaminski;RM Braziel;C Spier;DG Maloney;BD Cheson;TP Miller;RI Fisher
Journal / Conference
J Clin Oncol 30 (suppl; abstr 8001); American Society of Clinical Oncology 2012 Annual Meeting (June 1-5, 2012, Chicago, IL), oral presentation;
Year
2012
Research Committee(s)
Lymphoma
Study Number(s)
S0016

SWOG 0421: Prognostic and predictive value of bone metabolism biomarkers (BMB) in castration resistant prostate cancer (CRPC) patients (pts) with skeletal metastases treated with docetaxel +/- atrasentan (ATR)

Authors
P Lara;B Ely;D Quinn;C Tangen;E Gertz;M Hussain;N Vogelzang;I Thompson;M Van Loan
Journal / Conference
J Clin Oncol 30 (suppl; abstr 4547); American Society of Clinical Oncology 2012 Annual Meeting (June 1-5, 2012, Chicago, IL), poster discussion;
Year
2012
Research Committee(s)
Genitourinary
Study Number(s)
S0421

SWOG S0421: phase III study of docetaxel and placebo (P) for men with advanced castrate resistant prostate cancer

Authors
DI Quinn;C Tangen;M Hussain;P Lara;A Goldkorn;MG Garzotto;PC Mack;M Carducci;JP Monk;P Twardowski;P Van Veldhuizen;N Agarwal;CS Higano;N Vogelzang;IM Thompson
Journal / Conference
J Clin Oncol 30 (suppl; abstr 4511); American Society of Clinical Oncology 2012 Annual Meeting (June 1-5, 2012, Chicago, IL), oral presentation;
Year
2012
Research Committee(s)
Genitourinary
Study Number(s)
S0421

Results of circulating tumor cell counts using the CellSearch platform in a prospective randomized phase III SWOG-sponsored prostate cancer trial (S0421)

Authors
N Vogelzang;B Ely;LM Fink;A Goldkorn;C Tangen;P Twardowski;P Van Veldhuizen;N Agarwal;M Carducci;JP Monk;M Garzotto;PC Mack;PN Lara;C Higano;M Hussain;D Quinn;RJ Cote;IM Thompson
Journal / Conference
J Clin Oncol 30 (suppl; abstr 10503); American Society of Clinical Oncology 2012 Annual Meeting (June 1-5, 2012, Chicago, IL), oral presentation;
Year
2012
Research Committee(s)
Genitourinary
Study Number(s)
S0421

Results of telomerase activity measurements from live circulating tumor cells captured on a slot microfilter in a phase III SWOG-coordinated prostate cancer trial (S0421)

Authors
A Goldkorn;B Ely;DI Quinn;C Tangen;Y-C Tai;P Twardowski;P Van Veldhuizen;N Agarwal;M Carducci;JP Monk;MG Garzotto;PC Mack;PN Lara;CS Higano;M Hussain;N Vogelzang;RJ Cote;IM Thompson
Journal / Conference
J Clin Oncol 30 (suppl; abstr 4663); American Society of Clinical Oncology 2012 Annual Meeting (June 1-5, 2012, Chicago, IL), poster presentation;
Year
2012
Research Committee(s)
Genitourinary
Study Number(s)
S0421

A phase II study of PXD101 (belinostat) in relapsed and refractory aggressive b-cell lymphomas (rel/ref ABCL): SWOG S0520

Authors
D Perksy;S Bernstein;B Goldman;LM Rimsza;RI Fisher;TP Miller
Journal / Conference
J Clin Oncol 30 (suppl; abstr e18536);American Society of Clinical Oncology 2012 Annual Meeting (June 1-5, 2012, Chicago, IL), publication only;
Year
2012
Research Committee(s)
Lymphoma
Study Number(s)
S0520

SWOG S0533: A pilot trial of cisplatin (C)/Etoposide (E)/radiotherapy (RT) followed by consolidation docetaxel (LD) and bevacizumab (B) (NSC-704865) in three cohorts of patients (pts) with inoperable locally advanced stage III non-small cell lung cancer (NSCLC)

Authors
A Wozniak;J Moon;CR Thomas;K Kelly;PC Mack;LE Gaspar;D Raben;KJ Pandya;DR Gandara
Journal / Conference
J Clin Oncol 30 (suppl; abstr 7018);American Society of Clinical Oncology 2012 Annual Meeting (June 1-5, 2012, Chicago, IL), poster discussion
Year
2012
Research Committee(s)
Lung
Study Number(s)
S0533

Molecular marker analysis of SWOG S0636, a phase II trial of erlotinib and bevacizumab in never-smokers with advanced NSCLC

Authors
PC Mack;J Moon;H West;W Franklin;M Varella-Garcia;M Wynes;A Wozniak;M Redman;F Hirsch;D Gandara
Journal / Conference
J Clin Oncol 30, 2012 (suppl; abstr 7552); American Society of Clinical Oncology 2012 Annual Meeting (June 1-5, 2012, Chicago, IL), poster presentation;
Year
2012
Research Committee(s)
Lung
Study Number(s)
S0636

SWOG S0635 and S0636: Phase II Trials of Erlotinib (OSI-774)(E) and Bevacizumab (B) in Advanced (Adv) Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma with BAC Features (adenoBAC), or in Never-Smokers with Primary Adv NSCLC Adenocarcinoma (adenoCa)

Authors
H West;J Moon;F Hirsch;PC Mack;A Wozniak;D Lau;L Fehrenbacher;M Bury;M Redman;D Gandara
Journal / Conference
J Clin Oncol 30 (suppl; abstr 7517); American Society of Clinical Oncology 2012 Annual Meeting (June 1-5, 2012, Chicago, IL), poster discussion;
Year
2012
Research Committee(s)
Lung
Study Number(s)
S0635, S0636

A Phase II Trial of Azacitidine (NSC-102816) and Gemtuzumab Ozogamicin (NSC-720568) as Induction and Post-Remission Therapy in Patients of Age 60 and Older with Previously Untreated Non-M3 Acute Myeloid Leukemia (SWOG S0703): Report on the Good Risk Patients

Authors
S Nand;H Gundacker;JE Godwin;C Willman;T Norwood;H Erba;D Howard;S Coutre;M Othus;F Appelbaum
Journal / Conference
J Clin Oncol 30 (suppl; abstr 6502); American Society of Clinical Oncology 2012 Annual Meeting (June 1-5, 2012, Chicago, IL), oral presentation;
Year
2012
Research Committee(s)
Leukemia
Study Number(s)
S0703